Study Details

A study of oral dosing of ASP0456 in Patients with Chronic Constipation

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02809105

Astellas Study ID

The unique identification code given by the study sponsor.

0456-CL-1031

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Condition

Constipation

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

20 years - 79 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2016 - Nov 2017

Masking

Double (Participant, Investigator)

Enrollment number

186

Phase 3 Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and an Open-label, Uncontrolled, Long-term Dosing Study in Patients with Chronic Constipation (Not Including Constipation Due to Organic Diseases) -

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study of oral dosing of ASP0456 in Patients with Chronic Constipation? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00025

Saitama, Japan

Site JP00005

Tokyo, Japan

Site JP00003

Tokyo, Japan

Site JP00030

Aichi, Japan

Site JP00014

Tokyo, Japan

Site JP00037

Hyogo, Japan

Site JP00032

Osaka, Japan

Site JP00026

Saitama, Japan

Site JP00007

Tokyo, Japan

Site JP00010

Tokyo, Japan

Site JP00036

Osaka, Japan

Site JP00023

Chiba, Japan

Site JP00022

Chiba, Japan

Site JP00035

Osaka, Japan

Site JP00039

Hyogo, Japan

Site JP00031

Osaka, Japan

Site JP00027

Saitama, Japan

Site JP00013

Tokyo, Japan

Site JP00002

Hokkaido, Japan

Site JP00015

Tokyo, Japan

Site JP00001

Hokkaido, Japan

Site JP00019

Kanagawa, Japan

Site JP00034

Osaka, Japan

Site JP00024

Chiba, Japan

Site JP00021

Chiba, Japan

Site JP00008

Tokyo, Japan

Site JP00012

Tokyo, Japan

Site JP00028

Saitama, Japan

Site JP00020

Kanagawa, Japan

Site JP00018

Kanagawa, Japan

Site JP00011

Tokyo, Japan

Site JP00009

Tokyo, Japan

Site JP00029

Aichi, Japan

Site JP00038

Hyogo, Japan

Site JP00004

Tokyo, Japan

Site JP00017

Kanagawa, Japan

Site JP00040

Fukuoka, Japan

Site JP00033

Osaka, Japan

Site JP00006

Tokyo, Japan